It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multidrug and toxic compound extrusion (MATE) transport proteins confer multidrug resistance on pathogenic microorganisms and affect pharmacokinetics in mammals. Our understanding of how MATE transporters work, has mostly relied on protein structures and MD simulations. However, the energetics of drug transport has not been studied in detail. Many MATE transporters utilise the electrochemical H+ or Na+ gradient to drive substrate efflux, but NorM-VC from Vibrio cholerae can utilise both forms of metabolic energy. To dissect the localisation and organisation of H+ and Na+ translocation pathways in NorM-VC we engineered chimaeric proteins in which the N-lobe of H+-coupled NorM-PS from Pseudomonas stutzeri is fused to the C-lobe of NorM-VC, and vice versa. Our findings in drug binding and transport experiments with chimaeric, mutant and wildtype transporters highlight the versatile nature of energy coupling in NorM-VC, which enables adaptation to fluctuating salinity levels in the natural habitat of V. cholerae.
Raturi and Nair et al. describe functional ion pathways within the MATE transporter NorM from Vibrio cholerae (NorM-VC). By creating chimeric proteins and mutants of NorM-VC and NorM-PS, they dissect the localisation of ion-coupling events and roles of conserved catalytic carboxylates in H+ binding and Na+ coordination, with findings useful to the field of transporters and drug resistance pumps.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Cambridge, Department of Pharmacology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University College Dublin Clinical Research Centre, St. Vincent’s University Hospital, Dublin, Ireland (GRID:grid.7886.1) (ISNI:0000 0001 0768 2743)
2 University of Cambridge, Department of Pharmacology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
3 The University of Tokyo, Microbial Membrane Transport Engineering, Biotechnology Research Center, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
4 Tokyo Institute of Technology, Department of Life Science and Technology, Midori-ku, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)
5 The University of Tokyo, Laboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, Meguro-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)